Jasper Hellweg
Stock Analyst at Argus Research
(3.35)
# 821
Out of 4,667 analysts
87
Total ratings
48.33%
Success rate
3.56%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $364.33 | +9.79% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $131.68 | +13.91% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $47.78 | +25.58% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $743.35 | +57.40% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $451.23 | +21.89% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $63.20 | +34.49% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $105.27 | +18.74% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $36.94 | +278.99% | 4 | Sep 13, 2023 | |
| BIIB Biogen | Maintains: Buy | $320 → $350 | $156.00 | +124.36% | 3 | May 11, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $167.76 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $175.67 | +13.85% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $17.03 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $194.38 | +49.19% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $133.37 | -25.02% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $237.85 | +24.03% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $8.88 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $161.32 | -16.32% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $32.63 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $27.15 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $247.08 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $111.56 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $60.39 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $333.00 | -53.45% | 3 | Nov 6, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $364.33
Upside: +9.79%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $131.68
Upside: +13.91%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $47.78
Upside: +25.58%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $743.35
Upside: +57.40%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $451.23
Upside: +21.89%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $63.20
Upside: +34.49%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $105.27
Upside: +18.74%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $36.94
Upside: +278.99%
Biogen
May 11, 2023
Maintains: Buy
Price Target: $320 → $350
Current: $156.00
Upside: +124.36%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $167.76
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $175.67
Upside: +13.85%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $17.03
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $194.38
Upside: +49.19%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $133.37
Upside: -25.02%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $237.85
Upside: +24.03%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $8.88
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $161.32
Upside: -16.32%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $32.63
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $27.15
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $247.08
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $111.56
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $60.39
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $333.00
Upside: -53.45%